Abdallah Khaled, Gendron Louis
Département de pharmacologie-physiologie, Université de Sherbrooke, Sherbrooke, QC, Canada.
Institut de pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada.
Handb Exp Pharmacol. 2018;247:147-177. doi: 10.1007/164_2017_32.
Nowadays, the delta opioid receptor (DOPr) represents a promising target for the treatment of chronic pain and emotional disorders. Despite the fact that they produce limited antinociceptive effects in healthy animals and in most acute pain models, DOPr agonists have shown efficacy in various chronic pain models. In this chapter, we review the progresses that have been made over the last decades in understanding the role played by DOPr in the control of pain. More specifically, the distribution of DOPr within the central nervous system and along pain pathways is presented. We also summarize the literature supporting a role for DOPr in acute, tonic, and chronic pain models, as well as the mechanisms regulating its activity under specific conditions. Finally, novel compounds that have make their way to clinical trials are discussed.
如今,δ阿片受体(DOPr)是治疗慢性疼痛和情绪障碍的一个有前景的靶点。尽管DOPr激动剂在健康动物和大多数急性疼痛模型中产生的抗伤害感受作用有限,但它们在各种慢性疼痛模型中已显示出疗效。在本章中,我们回顾了过去几十年在理解DOPr在疼痛控制中所起作用方面取得的进展。更具体地说,介绍了DOPr在中枢神经系统内以及沿疼痛通路的分布情况。我们还总结了支持DOPr在急性、持续性和慢性疼痛模型中发挥作用的文献,以及在特定条件下调节其活性的机制。最后,讨论了已进入临床试验阶段的新型化合物。